Limerick

• Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Pending
  2024-519655-28-00 5 Premenopausal patients with high-risk HR-positive/HER2-negative breast
• Selective decontamination of the digestive tract in preventing surgical site infections in elective colorectal surgery: a randomised control … Pending
  2025-520725-20-00 4 Surgical site infection
• Single arm phase 2 trial of neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positiv … Recruiting
  2024-516582-36-00 10 2026-05-01 Early stage HER2-positive breast cancer
• A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax P … Recruiting
  2024-517131-52-00 5 2025-11-03 Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lym
• A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab … Recruiting
  2024-519827-16-00 5 2025-09-30 Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
• Study of Daraxonrasib (RMC-6236) in Patients with RAS Mutated NSCLC Recruiting
  2024-518154-16-00 5 2025-08-27 non-small cell lung cancer
• A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration ( … Recruiting
  2023-510294-34-00 5 2025-06-12 small lymphocytic lymphoma (SLL)
• EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting
  2023-506817-23-01 5 2025-05-23 Metastatic hormone naïve prostate cancer (mHNPC)
• A clinical study of zilovertamab vedotin with R-CHP treatment in people with diffuse large B-cell lymphoma (MK-2140-011) Recruiting
  2024-515526-89-00 4 2025-05-16 Diffuse Large B-Cell Lymphoma (DLBCL)
• A study of elritercept to treat transfusion-dependent anemia due to very low, low, or intermediate risk myelodysplastic syndromes Recruiting
  2024-516009-22-00 5 2025-04-30 myelodysplastic neoplasms/syndromes (MDS)
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting
  2024-512279-10-00 5 2024-11-25 Triple Negative Breast Cancer
• Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3) Recruiting
  2022-500587-35-01 5 2023-07-06 Stroke
• Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Dia … Recruiting
  2023-510384-36-00 5 2022-09-13 Newly Diagnosed Multiple Myeloma
• A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies Recruiting
  2023-504931-42-00 4 2021-04-06 Chronic lymphocytic leukemia/Small lymphocytic lymphoma; Richters tran
• Semaglutide for people with obesity and resistant hypertension (SUPPORT): a pilot, randomized, parallel-group, integrated, multicentre clini … Ended recruitment
  2024-513958-29-00 5 2025-04-24 Cardiovascular disorders: Hypertension and Obesity
• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended recruitment
  2024-512998-27-00 5 2025-02-21 Non-Small Cell Lung Cancer
• Add-Aspirin: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and surv … Ended recruitment
  2024-511306-23-00 5 2024-07-01 Breast cancer, colon cancer, rectal cancer, stomach cancer, oesophagea
• ETOP 22-22 ADEPPT: A study of adagrasib for patients with KRASG12C-mutant non-small cell lung cancer (NSCLC), who are elderly or who are unw … Ended recruitment
  2023-510463-35-00 4 2023-04-26 Patients with KRASG12C-mutant NSCLC, including patients aged ≥18 years
• A Phase 3 Study of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Ended recruitment
  2024-514173-22-00 5 2023-02-28 Cystic Fibrosis
• Study of ceralasertib plus durvalumab versus docetaxel for patients with advanced or metastatic non-small cell lung cancer Ended recruitment
  2023-509429-37-00 5 2022-10-03 Advanced or Metastatic Non-Small Cell Lung Cancer
• Isa-RVD Study: Phase II, Multi-centre, Single-Arm, Open-Label Study to evaluate the efficacy and safety of the combination regimen Isatuxima … Ended recruitment
  2024-512749-18-00 4 2022-03-03 Newly diagnosed Multiple Myeloma
• Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f … Ended recruitment
  2023-507961-24-00 5 2021-04-19 High-Risk HER2-Positive Breast Cancer
• Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended recruitment
  2023-507263-19-00 5 2020-12-23 Advanced Non-Small Cell Lung Cancer
• Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended recruitment
  2023-510390-33-00 5 2020-10-23 HER2-negative breast cancer patients with high relapse risk after stan

Showing 1–24 of 36 trials